Large-Cap & Specialty Pharmaceuticals
Branded pharmaceuticals; specialty pharma; rare-disease franchises; established-product portfolios.
NTM Growth %
to
EV / NTM Rev (x)
to
Mkt Cap ($B)
to
Showing 2 of 2 companies
| Company | Mkt Cap ↓ | EV | EV / LTM Rev | EV / NTM Rev | EV / LTM EBITDA | EV / NTM EBITDA | NTM Growth | Gross Margin | EBITDA Margin | FCF Margin | Rule of 40 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 3.9x | 3.9x | 12.7x | 12.1x | 2.9% | 66.3% | 21.1% | 13.9% | 16.8% | |||
| Mean | 3.9x | 3.9x | 12.7x | 12.1x | 2.9% | 66.3% | 21.1% | 13.9% | 16.8% | |||
| RHHBYRoche Holding AG | $352.00B | $374.00B | 5.9x | 5.9x | 17.2x | 18.2x | -0.4% | 73.3% | 34.5% | 23.3% | 22.9% | |
| BAYRYBayer AG | $54.86B | $87.13B | 2.0x | 1.9x | 8.2x | 6.1x | 6.2% | 59.3% | 7.7% | 4.6% | 10.8% |